The Edinburgh Investment Trust plc Issues Warning From Woodford

The portfolio manager of the Edinburgh Investment Trust plc (LON: EDIN), Neil Woodford, sees lower returns during the next three years.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

The shares of Edinburgh Investment Trust (LSE: EDIN) climbed 7p to 585p during early trade this morning despite the FTSE 250 member publishing half-year results that carried a warning from Neil Woodford.

Mr Woodford, who manages the portfolio owned by the Edinburgh trust through investment group Invesco Perpetual, cautioned that “returns over the next three years are likely to be somewhat lower than over the last three years, purely as a consequence of the higher valuations that we now see in our market.

He also claimed the withdrawal of “extraordinary” monetary policies in the US was “ultimately inevitable” and admitted he was worried about “the near-term implications of tapering” for equities.

While Mr Woodford added it was “more difficult than usual” to predict the path that the market could take over the next few months, he did reassure shareholders of the Edinburgh trust that their portfolio had “the potential to deliver an attractive positive return over more sensible, longer-time horizons.”

The trust’s half-year results showed the portfolio’s net assets advancing 2% to 592p per share with debt measured at par value.

Major holdings at the September half-year included Woodford favourites GlaxoSmithKline, AstraZeneca, BT, British American Tobacco and Roche.

Mr Woodford also took the opportunity to criticise recent political remarks about the utility sector.

Referring to the 20-month bill freeze proposed by the Labour Party, he described the economics of the policy as “absurd“.

Mr Woodford claimed:

We believe it is irrational for any privately-owned company to sell its products or services at a loss and we would encourage any company that was forced to do so to simply stop supplying.

Prices have not increased through company profiteering – there have been 20 separate inquiries into the energy market since 2001, none of which have found evidence of anti-competitive behaviour.

The Edinburgh trust has stakes in gas supplier Centrica and electricity generator SSE.

Last month Mr Woodford announced he would leave Invesco Perpetual in April to start his own fund-management business.

Jim Pettigrew, the chairman of the Edinburgh trust, said the board “would like to take some time to consider the options for the future management of the company before it makes a decision“.

Based on this morning’s share-price reaction, Edinburgh’s shares trade at about book value.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

> Maynard does not own any share mentioned in this article. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »